Drotrecogin alfa (activated)
Xigris (drotrecogin alfa (activated)) is a protein pharmaceutical. Drotrecogin alfa (activated) was first approved as Xigris on 2002-08-22. It has been approved in Europe to treat multiple organ failure and sepsis. The pharmaceutical is active against coagulation factor VIII and coagulation factor V.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| sepsis | HP_0100806 | D018805 | A41.9 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
112 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sepsis | D018805 | HP_0100806 | A41.9 | — | 2 | 4 | 5 | 8 | 19 |
| Toxemia | D014115 | — | — | — | 2 | 2 | 2 | 3 | 9 |
| Septic shock | D012772 | — | A48.3 | — | 1 | 2 | 2 | 3 | 8 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | — | — | 1 | 3 | 4 |
| Hemostatic disorders | D020141 | — | — | — | — | — | 1 | 3 | 4 |
| Shock | D012769 | — | R57.1 | — | 1 | 1 | 2 | — | 4 |
| Hematologic neoplasms | D019337 | — | — | 1 | 1 | — | 1 | — | 3 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | 1 | 2 | 3 |
| Intracranial hemorrhages | D020300 | EFO_0000551 | I62 | — | — | — | 1 | 1 | 2 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | 1 | 1 | 2 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 2 | 4 | 3 | — | — | 8 |
| Non-small-cell lung carcinoma | D002289 | — | — | 4 | 4 | 1 | — | — | 7 |
| Leukemia | D007938 | — | C95 | 2 | 3 | 1 | — | 1 | 5 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | 2 | 1 | — | 2 | 5 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 1 | 1 | — | 2 | 5 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 2 | 1 | — | — | 4 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 1 | 1 | 1 | — | 1 | 3 |
| Chronic renal insufficiency | D051436 | — | N18 | 1 | — | 1 | — | 1 | 3 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 2 | 1 | — | — | 3 |
| Hemophilia b | D002836 | — | D67 | — | 2 | 1 | — | — | 3 |
Show 9 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 5 | 7 | — | — | 1 | 12 |
| Melanoma | D008545 | — | — | 2 | 9 | — | — | — | 9 |
| Recurrence | D012008 | — | — | 1 | 3 | — | — | 1 | 5 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 2 | 4 | — | — | — | 5 |
| Multiple myeloma | D009101 | — | C90.0 | 3 | 1 | — | — | — | 4 |
| Covid-19 | D000086382 | — | — | 1 | 1 | — | — | 2 | 4 |
| Colorectal neoplasms | D015179 | — | — | 2 | 2 | — | — | — | 3 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 2 | — | — | — | 3 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | — | 3 | — | — | — | 3 |
| Glioma | D005910 | EFO_0000520 | — | 1 | 2 | — | — | — | 3 |
Show 72 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | 1 | 3 |
| Inflammation | D007249 | MP_0001845 | — | 1 | — | — | — | 2 | 3 |
| Fibrosis | D005355 | — | — | 1 | — | — | — | 1 | 2 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 2 | — | — | — | — | 2 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | — | 1 |
| Meningioma | D008579 | EFO_0003098 | D32.9 | 1 | — | — | — | — | 1 |
| Astrocytoma | D001254 | EFO_0000271 | — | 1 | — | — | — | — | 1 |
| Choroid plexus neoplasms | D016545 | EFO_0007206 | — | 1 | — | — | — | — | 1 |
| Oligodendroglioma | D009837 | EFO_0000631 | — | 1 | — | — | — | — | 1 |
| Ganglioglioma | D018303 | — | — | 1 | — | — | — | — | 1 |
Show 10 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | — | — | 2 | 2 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 2 | 2 |
| Candidemia | D058387 | EFO_1001282 | — | — | — | — | — | 1 | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Portal hypertension | D006975 | EFO_0000666 | K76.6 | — | — | — | — | 1 | 1 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | — | — | 1 | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | — | — | 1 | 1 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | — | — | — | 1 | 1 |
| Sclerosis | D012598 | — | — | — | — | — | — | 1 | 1 |
| Appendicitis | D001064 | EFO_0007149 | K37 | — | — | — | — | 1 | 1 |
Show 51 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Drotrecogin alfa (activated) |
| INN | drotrecogin alfa (activated) |
| Description | Drotrecogin alfa (activated) (Xigris, marketed by Eli Lilly and Company) is a recombinant form of human activated protein C that has anti-thrombotic, anti-inflammatory, and profibrinolytic properties. Drotrecogin alpha (activated) belongs to the class of serine proteases. Drotrecogin alfa has not been found to improve outcomes in people with severe sepsis. The manufacturer's aggressive strategies in marketing its use in severe sepsis have been criticized. On October 25, 2011, Eli Lilly & Co. withdrew Xigris from the market after a major study showed no efficacy for the treatment of sepsis.
|
| Classification | Unknown |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2109065 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00055 |
| UNII ID | JGH8MYC891 (ChemIDplus, GSRS) |
Target
Agency Approved
F8
F8
F5
F5
Organism
Homo sapiens
Gene name
F8
Gene synonyms
F8C
NCBI Gene ID
Protein name
coagulation factor VIII
Protein synonyms
AHF, Antihemophilic factor, coagulation factor VIII A1 domain, coagulation factor VIII C2 domain, coagulation factor VIII, procoagulant component, coagulation factor VIIIc, factor VIII F8B, Procoagulant component
Uniprot ID
Mouse ortholog
F8 (14069)
coagulation factor VIII (Q06194)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 12,538 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,371 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use